1992. 5. 13. Enacted
2017. 2. 22. Revised
2017. 5. 17. Revised
2018. 5. 21. Revised
2018. 11. 23. Revised
2021. 12. 1. Revised
2024. 12. 3. Revised
2025. 5.28. Revised

Table of Contents

• • RESEARCH AND PUBLICATION ETHICS
• • MANUSCRIPT PREPARATION
• • MANUSCRIPT SUBMISSION
• • PEER REVIEW AND PUBLICATION PROCESS

Acute and Critical Care (Acute Crit Care, ACC) is the official scientific journal of the Korean Society of Critical Care Medicine (KSCCM), with the purpose of publishing research and therapeutic achievements in the field of critical care medicine. ACC is published quarterly on the last day of February, May, August, and November. Manuscripts submitted to ACC should be written according to the following instructions for authors. The Editorial Board will make all final decisions regarding acceptance of submitted manuscripts and the publication order of accepted manuscripts. The Editorial Board considers ethics, rationality, originality, and scientific impact when accepting submitted manuscripts, and may request further revision of articles when necessary.

RESEARCH AND PUBLICATION ETHICS

ACC adheres to the recommendations and policies on research and publication ethics established by the International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org) and the Committee on Publication Ethics (COPE, https://publicationethics.org). ACC also follows the Principles of Transparency and Best Practice in Scholarly Publishing, jointly developed by the COPE, DOAJ, WAME, and OASPA (https://publicationethics.org/resources/guidelines-new/principles-transparency-and-best-practice-scholarly-publishing). In cases of research or publication misconduct, editorial decisions are made in accordance with COPE flowcharts.

Statement of Human and Animal Rights and Informed Consent

Any investigations involving humans or animals must be approved by the Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC) of the institution where the study was conducted. Human research must follow the ethical principles of the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects) and animal research must comply with national or institutional guidelines for animal care and use. ACC does not consider any studies involving humans or animals that do not have appropriate ethical approval.

Informed consent must be obtained from all human participants unless this requirement is waived by the relevant IRB. Authors should indicate whether informed consent was obtained, and specify its form (e.g., written or verbal). For studies involving vulnerable populations (such as children or individuals with cognitive impairment), consent must be obtained from legally authorized representatives, and appropriate ethical safeguards must be described.

Identifiable personal information (e.g., names, initials, hospital numbers, or dates of birth) should not be included. Images of human subjects may be used only when scientifically necessary and when explicit permission has been obtained. Even with consent, identifying features should be removed unless essential. If images are modified to ensure anonymity, the authors must confirm that such modifications do not compromise scientific integrity. Formal consent is not required for fully anonymized images (e.g., radiographs or pathology slides) with no identifying features or accompanying text. However, partial anonymization (e.g., eye bars or blurring) is not sufficient if consent has not been obtained.

For case reports or case series, written informed consent for publication must be obtained from the patient or the patient’s legal representative regardless of whether identifying information is included. A statement confirming this must be included in the manuscript.

All original articles must clearly state whether the study received approval from an IRB and/or IACUC, and whether informed consent was obtained. ACC may request supporting documentation if necessary. Authors are fully responsible for the content and ethical integrity of their work.

Registration of Clinical Trial Research

Any research involving clinical trials should be registered with the primary national clinical trial registry such as the Korea Clinical Research Information Service (http://cris.nih.go.kr) or other sites accredited by the World Health Organization (https://www.who.int/tools/clinical-trials-registry-platform) or International Committee of Medical Journal Editor such as ClinicalTrials.gov (https://clinicaltrials.gov).

Conflicts of Interest

Conflicts of interest exist when authors, reviewers, or editors have financial, personal, or professional relationships that could inappropriately influence—or be perceived to influence—their actions or judgments.

Authors must disclose any potential conflicts of interest that are directly or indirectly related to the submitted work. Relevant conflicts include, but are not limited to: research grants or funding (e.g., from industry, government, or foundations); consulting or advisory roles for related companies; ownership of stocks or shares in related entities; patent applications or licenses related to the subject matter; honoraria; travel support; paid expert testimony; and personal or professional relationships, including academic rivalry or intellectual bias.

All disclosures must be included in a dedicated "Conflicts of Interest" section in the manuscript and clearly indicated on the title page. All sources of financial support—including the name of the funding agency, grant number, and country—should be listed in the funding section on the title page. Authors must also complete and submit the ICMJE Conflict of Interest Disclosure Form (https://www.icmje.org/disclosure-of-interest). If there are no conflicts of interest, authors should state: “The authors have no conflicts of interest to declare.” Disclosed conflicts should be described objectively and separately from scientific content. Disclosure does not imply bias but rather ensures transparency so that editors, reviewers, and readers can interpret the work in context.

Authorship

As stated in the ICMJE recommendations, credit for authorship requires: (1) substantial contributions to conception and design or to data acquisition, analysis, or interpretation; (2) drafting of the article or critical revision for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to accuracy or integrity of any part of the article are appropriately investigated and resolved. Only those who meet all four criteria should be listed as authors. Individuals who contributed to the work but do not meet all criteria (e.g., those providing technical support, general supervision, or writing assistance) should be acknowledged as contributors, not listed as authors.

If the number of authors is equal to or greater than 2, each author’s specific contribution must be described at submission. Authors are encouraged to use CRediT (Contributor Roles Taxonomy) to define their contributions (e.g., conceptualization, data curation, formal analysis, methodology, writing original draft, etc.). Any requests to change authorship (e.g., addition, deletion, or rearrangement) before publication must be submitted to the editorial office with following: (1) a letter explaining the reason for the change, signed by all authors including those being added or removed, and (2) a revised title page reflecting the change. After publication, authorship changes will be allowed only under exceptional circumstances and must comply with COPE guidelines.

In the cover letter, the corresponding author must confirm that all listed authors fulfill the ICMJE authorship criteria and that no eligible contributor has been omitted.

Originality and Duplicate Publication

All submitted manuscripts must be original and not under review or published elsewhere. Duplicate submissions will not be accepted. No part of materials published in ACC may be reproduced without prior permission from the Editorial Board.

Authors are responsible for obtaining copyright when reusing figures or tables from other sources. Reuse without permission is allowed only for materials under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) with proper citation (https://creativecommons.org/licenses/by-nc/4.0). For materials from non-open-access publications or those not covered by a Creative Commons license, authors must obtain written permission and clearly indicate the original source.

Secondary Publication

ACC allows secondary publication if it complies the ICMJE guidelines (https://www.icmje.org). This applies to articles such as clinical guidelines, consensus statements, or educational materials with public health or professional importance intended for a broader or international audience. Secondary publication is permitted when all of the following conditions are met:

(1) Approval must be obtained from the editors of both the primary and secondary journals; (2) The primary publication should be clearly identified and cited in the secondary version; (3) A sufficient publication interval—typically at least one week—should be observed unless both editors agree otherwise; (4) The secondary version must accurately reflect the data and interpretation of the original; and (5) The secondary version should be intended for a different group of readers, such as through translation or regional adaptation. The title page of the secondary publication must include a footnote, for example: “This article is based on a study first published in [journal title, full reference].”

Management of Research and Publication Misconduct

In cases of suspected research or publication misconduct—such as duplicate publication, plagiarism, data fabrication or falsification, authorship disputes, undisclosed conflicts of interest, ethical concerns, reviewer misconduct, or complaints against editors—ACC follows the flowcharts provided by the COPE (https://publicationethics.org/guidance). All cases are reviewed and decided by the Editorial Board.

Editorial Responsibilities

The Editorial Board will continuously work to monitor/safeguard publication ethics, including guidelines for retracting articles; maintaining the integrity of the academic record; preclusion of business needs from compromising intellectual and ethical standards; publishing corrections, clarifications, retractions, and apologies when needed; and ensuring that there is no plagiarism and no fraudulent data in publications. Editors maintain the following responsibilities: the responsibility and authority to reject/accept articles; ensuring there are no conflicts of interest with respect to articles; accepting papers only when reasonably certain of their validity; promoting the publication of corrections or retractions when errors are found; and preserving the anonymity of reviewers.

MANUSCRIPT PREPARATION

Manuscripts should be written in English. Medical terminology should conform to the most recent edition of Dorland’s Illustrated Medical Dictionary.

1. General Principles

1) Word processors and format of manuscript
Manuscripts should be submitted in the file format of Microsoft Word 2003 or higher. Manuscripts should be typed on an A4-sized document, be double-spaced, and use a font size of 12 point with margins of 2 cm on each side and 3 cm for the upper and lower ends. Double spaces should be left between the lines.

2) Abbreviation of terminology
Abbreviations should be avoided as much as possible. One word should not be expressed through an abbreviation, although more than two words may be expressed through an abbreviation. The full term for which the abbreviation stands should be used at its first occurrence in the text. Abbreviations should not be present in the title. Common abbreviations, however, may be used, such as DNA.

3) Units
The use of International Standardized (SI) units is encouraged. These are available at https://physics.nist.gov/cuu/Units/index.html or https://physics.nist.gov/cuu/pdf/sp811.pdf.

4) Machine and equipment
When the use of reagents or devices is reported in the text, the name of the manufacturer should be indicated.

5) Statistics
Statistical methods must be described and the program used for data analysis, and its source, should be stated.

6) Arrangement of manuscript
The article should be organized in the order of Title page, Abstract, Introduction, Materials and Methods, Results, Discussion, Conflict of Interest, Acknowledgments, Open Researcher and Contributor ID (ORCID), Authors’ contributions, References, Table, Figure, and Figure Legends.
The title of each new section should begin on a new page. Number pages consecutively, beginning with the abstract page. Page numbers should be placed at the middle of the bottom of each page.

7) Reporting guidelines for specific study designs
Research reports frequently omit important information. As such, reporting guidelines have been developed for a number of study designs that some journals may ask authors to follow. Authors are encouraged to also consult the reporting guidelines relevant to their specific research design. A good source for reporting guidelines is the EQUATOR Network (http://www.equator-network.org/home/) and the United States National Institutes of Health/National Library of Medicine (http://www.nlm.nih.gov/services/research_report_guide.html).

2. Organization of Manuscript – Original Article

All articles must be organized in the following order:
The Title page and Main page files should be uploaded separately.

1) Title page

• ① Title: The title should be concise and precise. Only the first letter of the first word in the title should be capitalized. The title should use generic drug names, not brand names.
• ② Authors and affiliations: First, middle, and last names should be included for each author. If the author is affiliated with multiple departments, this should be included in a footnote by their name. If authors are affiliated with multiple departments and hospitals, affiliations should be arranged in the order of authors and demarcated with a number.
• ③ Running head: A running head of no more than 50 characters including letters and spaces should be included in English. If the included running head is inappropriate, the Editorial Board may revise it.
• ④ Corresponding author: The corresponding author’s name, postal code, address, telephone number, fax number, e-mail address should be included.
• ⑤ Conflict of Interest
  If there are any conflicts of interest, authors should disclose them in the manuscript. Disclosures allow editors, reviewers, and readers to approach the manuscript with an understanding of the situation and background of the completed research. If there are no conflicts of interest, authors should include following sentence: “No potential conflict of interest relevant to this article was reported.”
• ⑥ Funding
  Funding for the research should be provided here. Providing a FundRef ID is suggested, including the name of the funding agency, the country, and if available, the number of the grant provided by the funding agency. If the funding agency does not have a FundRef ID, please ask the agency to contact the FundRef registry (e-mail: fundref.registry@crossref.org). A detailed description of the FundRef policy can be found at http://www.crossref.org/fundref/.
• ⑦ ORCID (Open Researcher and Contributor ID)
  All authors are recommended to provide an ORCID. To obtain an ORCID, authors should register at the ORCID website: https://orcid.org. Registration is free for all researchers.
• ⑧ Authors’ contributions
  The work authors have conducted for the study should be described in this section. To qualify for authorship, all contributors must meet at least one of the seven core contributions by CRediT (conceptualization, methodology, software, validation, formal analysis, investigation, data curation), as well as at least one of the writing contributions (original draft preparation, review, and editing). Authors may also satisfy the other contributions; however, these alone will not qualify them for authorship. Contributions will be published with the final article and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and it is expected that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time. The information concerning sources of author contributions should be included in this section at the submission of the final version of the manuscript (at the first submission, this information should be included in the title page).
  Examples of authors’ contributions are as follows:
  Conceptualization: MHC. Data curation: JH. Formal analysis: YIA. Funding acquisition: MHC. Methodology: MHC, JH, YIA. Project administration: YIA. Visualization: MHC, JH, YIA. Writing – original draft: JH, YIA. Writing – review & editing: MHC, JH, YIA.
• ⑨ Acknowledgments
  Individuals or institutions that contributed to the paper but whose contributions were not substantial enough to warrant co-authorship may be acknowledged in a separate section. Financial support, including foundations, institutions, pharmaceutical and device manufacturers, private companies, intramural departmental sources, or any other support should be described.

2) Main page

• ① Abstract
  All manuscripts should contain a structured abstract. Abstracts should be no more than 250 words in length and must have the following headings: Background, Methods, Results, and Conclusions. The quotation of references must not be included in the abstract.
• ② Keywords
  A maximum of 6 keywords should be listed, immediately after the abstract, in alphabetical order. Each key word should be separated by a semicolon (;). The authors should use MeSH (Medical Subject Heading) terms in their key words (https://meshb.nlm.nih.gov/).
• ③ Key Messages
  A list of 2 or 3 key messages is required. This provides a quick structured synopsis of the important findings of your manuscript and their meaning. This section is limited to 50-100 words or less.
• ④ Introduction
  The introduction should address the purpose of the article concisely and include background reports that are relevant to the purpose of the paper.
• ⑤ Materials and Methods
  When reporting experiments with human or animal subjects, the authors should indicate whether they received approval from the IRB for the study, and agreement from the patients. When reporting experiments with animal subjects, the authors should indicate whether the handling of animals was supervised by the Institutional Board for the Care and Use of Laboratory Animals. Sufficient details need to be addressed in the methodology section of an experimental study so that it can be further replicated by others. Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial, or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study involved an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should also define how they determined race or ethnicity and justify their relevance. If it is necessary to include institutional affiliations, the names of institutions should be blinded to ensure anonymity.
• ⑥ Results
  Results should be presented in a logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat all of the data in the tables or illustrations in the text; emphasize or summarize only the most important observations.
• ⑦ Discussion
  Discussion should emphasize the new and important aspects of the study, including the conclusions. Do not repeat the results in detail or other information that is included in the Introduction or Results sections. Describe the conclusions according to the purpose of the study but avoid unqualified statements that are not adequately supported by the data. Conclusions may be stated briefly in the last paragraph of the Discussion section.
• ⑧ References
  References should be obviously related to the document and cited in sequential order in the text. The description of the Reference section is provided below. The References follow the NLM Style Guide for Authors, Editors, and Publishers (http://www.nlm.nih.gov/citingmedicine) if not specified below.
  References should be identified in text with full-size Arabic numerals on the line and in square brackets [ ]. All of the references should be stated in English, including author, title, and name of journal. If necessary, the reviewers and the Editorial Board may request original documents of the references. In the Reference section, journals should be abbreviated according to the style used in the list of journals indexed in the NLM Journal Catalog (http://www.ncbi.nlm.nih.gov/nlmcatalog/journals). Journal titles that are not listed in the Catalog should follow the ISO abbreviation as described in “ISO 4:1997 Information and documentation--Rules for the abbreviation of title words and titles of publications” (http://www.iso.org/iso/home/store/catalogue_tc/catalogue_detail.htm?csnumber=3569).
  Up to six authors may be listed. If a reference has more than six authors, only list the first six authors with “et al.” Provide the start and end page numbers of the cited reference.
  • Examples of reference style
    A. Journal Article
    Authors. Article title. Journal title Published year;Volume: Start-End page.
    1. Lee DH, Kim EY, Seo GJ, Suh HJ, Huh JW, Hong SB, et al. Global and regional ventilation during high flow nasal cannula in patients with hypoxia. Acute Crit Care 2018;33:7-15.
    2. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24.
    3. Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I. Analysis and assessment of abinitio three-dimensional prediction, secondary structure, and contacts prediction. Proteins 1999;43(Suppl 3):149-70.
    
    B. Book
    Authors. Book title. Edition*. Publisher; Published year.
    *Mark edition if it is beyond the 2nd edition.
    4. Nuwer MR. Evoked potential monitoring in the operating room. 2nd ed. Raven Press; 1986.
    
    C. Book Chapter
    Authors of chapter. Title of chapter. In: Editors of book, editor(s). Title of book. Edition. Publisher; Published year. p. Start-End page.
    5. Blitt C. Monitoring the anesthetized patient. In: Barash PG, Cullen BF, Stoelting RK, editors. Clinical anesthesia. 3rd ed. Lippincott-Raven; 1997. p. 563-85.
    
    D. Electronic Format
    • Electronic publication before print
      6. Lee OJ, Cho YH, Hwang J, Yoon I, Kim YH, Cho J. Long-term extracorporeal membrane oxygenation after severe blunt traumatic lung injury in a child. Acute Crit Care 2017 Feb 10 [Epub]. https://doi.org/10.4266/acc.2016.00472
    • Website
      7. Sage Terapeutics. A study with SAGE-547 for superrefractory status epilepticus [Internet]. U.S. National Library of Medicine; 2000 [cited 2016 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02477618?term=NCT02477618&rank=1
• ⑨ Tables
  • • Each table should be consecutively typed or printed on a separate sheet of paper in the order of citation in the text.
  • • Supply a brief title at the top of the table. The titles of tables start with “Table 1.”
  • • Footnotes should be provided consecutively in order of the information, statistics, and abbreviations. Footnoted information should be referenced using superscript small letters (ex; a, b) in alphabetical order.
• ⑩ Legends of Figures and Illustrations
  All figures and photographs must be described separately within the text. The description order must be the same as in the footnotes in tables and should be in recognizable sentences. In microscopic pictures, staining methods and magnification ratio should be indicated.

3) Figures and Illustrations

• • ACC publishes in full color and encourages authors to use color to increase the clarity of figures. Authors must submit figures and illustrations as electronic files.
• • Figures should be submitted as separate electronic files:
  • - TIFF format is preferred.
  • - JPEG is acceptable if it is the original format.
• • Each figure must be of good quality, higher than 300 dpi resolution with good contrast and sharpness. Figures must be sized to 4 inches. If possible, submit the original file without any modifications.
• • Submit files of figures and photographs separately from the text of the paper. Number figures as “Figure Arabic numeral” in the order of their citation (ex. Figure 1). If a figure is divided into more than two images, mark each figure with Arabic numerals and a capital letter (Ex. Figure 1A, Figure 1B).
• • Authors should submit line drawings in black and white.
• • Figures should be explained briefly in the titles.
• • An individual should not be recognizable in photographs or X-ray films provided at the time of submission.
• • Radiographic prints must have arrows for clarity if applicable.
• • Pathological samples should be pictured with a measuring stick

3. Organization of Reviews

The Editorial Board requests review articles of particular titles and text. Author can describe text that is not itemized. Review articles should include unstructured abstracts equal to or less than 250 words in English. Key words should follow ordinary processes. The length of the text excluding references, tables, and figures should not exceed 5,000 words.

4. Organization of Letters to the Editor

Letters to the Editor should include brief constructive comments that concern a published article; a short, free-standing opinion; or a short, interesting case. Letters to the Editor should be submitted no more than 6 months after the relevant paper has been published. The main text should not exceed 1,000 words and the total number of references is limited to 5. Letters may be edited by the Editorial Board, and if necessary, responses from the author of the relevant paper may be provided. The responses should have the same format of Letters to Editor.

5. Images in Critical Care

The images section must be of high scientific quality and value and provide didactic and self-explanatory lessons. Images must be unique and adhere to ethical standards with patient/relative approval when appropriate and ensure protection of patient identity and privacy.
The total text should not exceed 200 words. A maximum of five authors is permitted. Up to 5 references are allowed. No abstract is required.
The legend for the image should concisely present relevant clinical information, including a short description of the patient’s history, relevant physical and laboratory findings, clinical course, response to treatment (if any), and condition at last follow-up. All labeled structures in the image should be described and explained in the legend.

6. Other Publication Types

Other publication types such as guidelines, brief reports, and history articles may be accepted. The recommended format can be discussed with the Editorial Board.

MANUSCRIPT SUBMISSION

1. Submission Process

1. Authors are requested to submit their papers electronically using the online manuscript submission system available at: http://submit.accjournal.org/. Under this online system, only corresponding authors and first authors can submit manuscripts. The process of reviewing and editing will be conducted entirely through this system.
2. Authors and reviewers may check the progress of reviews and related questions/answers on this system. All progress in reviews will also be informed to corresponding authors.
3. Upon submission of a manuscript, authors should send a statement of copyright release and author agreement, which must be signed by all authors, by scanned file to the Editorial Office.
4. A proof by authors should be submitted within one week of the request.
5. During submission process, the authors ORCIDs will be requested. The corresponding author’s ORCIDs is mandatory.

2. Article Processing Charge

There are no author submission fees. All costs for the submission process are supported by the Publisher.

3. Contact

For queries about manuscript submission, please contact:
Editorial Office #805-806, Yongseong Biztel, 109 Hangang-daero, Yongsan-gu, Seoul 04376, Korea
Tel: +82-2-2077-1533, Fax: +82-2-2077-1535,
E-mail: acc@accjournal.org

PEER REVIEW AND PUBLICATION PROCESS

1. Screening after Submission

1. Screening process will conducted after submission. If the manuscript does not fit the aims and scope of the Journal or does not adhere to the Instructions to authors, it may be returned to the author immediately after receipt and without a review.
2. Before reviewing, all submitted manuscripts are inspected by Similarity Check powered by iThenticate (https://www.crossref.org/services/similarity-check/), a plagiarism-screening tool. If a too high a degree of similarity score is found, the Editorial Board will do a more profound content screening.
3. The criterion for similarity rate for further screening is usually 15%; however, the excess amount of similarity in specific sentences may be also checked in every manuscript. The settings for Similarity Check screening are as follows: It excludes quotes, bibliography, small matches of 6 words, small sources of 1%, and the Methods section.

2. Peer Review Process

Under no circumstances will the identities of the reviewers be disclosed.
Additionally, the reviewers will remain blinded to the names of the authors and their affiliated institutions.

1. Submitted manuscripts will be reviewed by 2 or more experts in the corresponding field. The Editorial Board may request authors to revise the manuscripts according to the reviewer’s opinion. After revising the manuscript, the author should upload the revised files with a reply to each item of the reviewer’s opinion. The revised part should be marked as red font with underline.
2. The author’s revisions should be completed within 30 days after the request. If it is not received by the due date, the Editorial Board will not consider it for publication again.
3. The manuscript review process typically concludes after the second round of review. If further revision is requested, the Editorial Board may consider it.
4. The Editorial Board may request authors to correct English to reach a certain standard and authors should accept the request.
5. The Editorial Board will make a final decision on the approval of the submitted manuscript for publication and can request any further corrections, revisions, and deletions of the article text if necessary. Statistical editing is also performed if the data requires professional statistical review by a statistician.

3. Process after Acceptance

If the manuscript is finally accepted, the proofreading will be sent to the corresponding author after professional manuscript editing and/or English proofreading. Proofreading should be performed again for any misspellings or errors by the authors.
Before final proofreading, the manuscript may appear at the journal homepage as an epub ahead of print with a unique DOI number for rapid communication. The epub ehead of print version will be replaced by the replacement XML file and a final PDF.

4. Fee for Publication and Reprints

There is no article processing charge but an additional fee for reprints or color prints will be charged to authors. However, this policy could be changed in the future.

5. Copyright and Open access

Copyrights ownership is to be transferred to the KSCCM. The authors should submit “Authorship Responsibility and License Agreement Form” at the time of manuscript submission. This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

6. Clinical Data Sharing Policy

ACC accepts the ICMJE recommendations for data sharing statement policy (http://icmje.org/icmje-recommendations.pdf). All manuscripts reporting clinical trial results are recommended to submit a data sharing statement following the ICMJE guidelines from 1 January 2019. Authors may refer to the editorial, “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors,” in JKMS Vol. 32, No. 7:1051-1053 (http://crossmark.crossref.org/dialog/?doi=10.3346/jkms.2017.32.7.1051&domain=pdf&date_stamp=2017-06-05).